सभी अध्ययन
आमंत्रण द्वारा नामांकनचरण 2हस्तक्षेपात्मक

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

This research is a continuation of an earlier study focusing on Myotonic Dystrophy Type 1 (DM1). Myotonic Dystrophy Type 1 is a condition that causes muscle weakness and other problems. Scientists want to see how safe a new medicine, called VX-670, is when taken for a longer period. They also want to check if it continues to help with the symptoms of DM1 and how the body handles the medicine over time. Only people who have already taken part in a specific previous study involving VX-670 can join this long-term follow-up research.

एक नजर में

स्थिति
आमंत्रण द्वारा नामांकन
चरण
चरण 2
प्रायोजक
वर्टेक्स फार्मास्यूटिकल्स इनकॉर्पोरेटेड
नामांकन लक्ष्य
44
प्रारंभ
28 Apr 2025
अनुमानित पूर्णता
30 जनवरी 2029

यह अध्ययन किस बारे में है?

This study is all about understanding a new medicine called VX-670, which is being developed for people living with Myotonic Dystrophy Type 1, often shortened to DM1. DM1 is a condition that affects muscles, causing them to gradually weaken and making everyday tasks harder. It can also impact other parts of the body.

The main goal of this particular research is to carefully watch what happens when people take VX-670 over a longer period. The researchers want to make sure it's safe and doesn't cause unexpected problems. They're also keen to see if the medicine continues to work well in managing the symptoms of DM1 and how the body processes it over time.

This study is essentially a follow-up for people who have already started treatment with VX-670 in a previous study. By continuing to gather information, doctors and scientists hope to learn more about how this potential new treatment could improve the lives of people with DM1 in the long run.

मुख्य निष्कर्ष

  • This study is for people already taking the medicine VX-670 for Myotonic Dystrophy Type 1.
  • It aims to understand the long-term safety and effects of VX-670.
  • Participants must have completed a previous related study.
  • The study includes adults aged 18 and over, both men and women.
  • This is a Phase 2 study, focused on continued safety and how well the treatment works over time.

कौन पात्र हो सकता है?

To join this study, there are some specific requirements. The most important one is that you must have already taken part in a previous study about the same medicine, VX-670. This previous study was called VX23-670-001.

There are also some things that would prevent you from taking part. For example, if you have any other serious health conditions that are outlined in the study plan, you might not be able to join. These conditions are carefully chosen to make sure the study is safe for everyone involved and that the results are clear.

Overall, the study is open to both men and women who are 18 years old or older. The research team will check all your details carefully to see if this study is right for you.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. Did I already take part in the study called VX23-670-001?
  2. क्या मैं 18 वर्ष का या उससे अधिक उम्र का हूँ?
  3. Do I have Myotonic Dystrophy Type 1 (DM1)?
  4. Do I have any other major health issues that might prevent me from joining?
  5. Have I discussed this study with my doctor?
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you are eligible and agree to take part, your involvement would typically include regular visits to a clinic. During these visits, the study team would perform various assessments to check your health, monitor any side effects, and see how the medicine is working. This might involve physical examinations, blood tests, and questionnaires about your symptoms and how you are feeling. You would continue to take the study medicine, VX-670, as directed by the research team. The total duration of your participation would depend on the study's plan, but it's designed to look at the long-term effects of the medication.

संभावित जोखिम और लाभ

Taking part in this study could potentially offer some benefits, such as continued access to a new experimental medicine (VX-670) and close monitoring of your health by medical professionals. However, as with any medicine, there are potential risks, including side effects from the treatment. The research team will explain all known risks to you. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (16)

  • St. Louis Children's Hospital - Neurology
    सत्यापित पोस्टकोड
    सेंट लुइस, संयुक्त राज्य अमेरिका
  • Wake Forest Univ School of Medicine - Neurology
    सत्यापित पोस्टकोड
    विंस्टन-सलेम, संयुक्त राज्य अमेरिका
  • Virginia Commonwealth University - Sanger Hall
    सत्यापित पोस्टकोड
    रिचमंड, संयुक्त राज्य अमेरिका
  • Wesley Research Institute
    सत्यापित पोस्टकोड
    Auchenflower, Australia
  • Neuroscience Clinical Trials Unit, Alfred Brain
    सत्यापित पोस्टकोड
    मेलबर्न, ऑस्ट्रेलिया
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Pulmonology
    सत्यापित पोस्टकोड
    ल्यूवेन, बेल्जियम
  • Altasciences Montreal
    सत्यापित पोस्टकोड
    मॉन्ट्रियल, कनाडा
  • Montreal Neurological Institute-Hospital
    सत्यापित पोस्टकोड
    मॉन्ट्रियल, कनाडा
  • ओटावा विश्वविद्यालय
    सत्यापित पोस्टकोड
    ओटावा, कनाडा
  • Universite Laval - Neurology
    सत्यापित पोस्टकोड
    क्यूबेक, कनाडा
  • Friedrich Baur Institute
    सत्यापित पोस्टकोड
    म्यूनिख, जर्मनी
  • Maastricht UMC
    सत्यापित पोस्टकोड
    मास्ट्रिच, नीदरलैंड्स

सामान्य प्रश्न

What is Myotonic Dystrophy Type 1 (DM1)?

DM1 is a condition that causes muscles to weaken over time. It can also affect other parts of the body.

What is VX-670?

VX-670 is the name of the new medicine being tested in this study for DM1.

Which phase is this study in?

This study is in Phase 2, which means researchers are checking the medicine's safety and effectiveness in a larger group of people.

Can anyone with DM1 join this study?

No, you must have already taken part in a specific previous study about VX-670 to be eligible for this one.

अध्ययन कितने समय तक चलेगा?

This is a 'long-term' study, meaning it will track participants over an extended period to monitor the medicine's effects over time.

और अधिक जानने के लिए कैसे पता करें

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

भाग लेने में रुचि रखते हैं?

अपनी रुचि दर्ज करें

अपने विवरण साझा करें और अनुसंधान टीम के लिए "A Study of Long-term Safety and Efficacy of VX-670 in Partic…यदि आप पात्र हो सकते हैं तो आपसे संपर्क करेंगे। भाग लेने के लिए सहमति देने से पहले हमेशा अपने जीपी से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.